{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:41:55Z","timestamp":1792788115741,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2024-00334982"],"award-info":[{"award-number":["RS-2024-00334982"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010418","name":"Institute for Information and Communications Technology Promotion","doi-asserted-by":"publisher","award":["IITP-2026-RS-2020-II201808"],"award-info":[{"award-number":["IITP-2026-RS-2020-II201808"]}],"id":[{"id":"10.13039\/501100010418","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS-2025-25446266"],"award-info":[{"award-number":["RS-2025-25446266"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"DOI":"10.1007\/s00417-026-07581-x","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:15:54Z","timestamp":1792725354000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adjunctive topical bromfenac and the 3-year bevacizumab injection burden in macular edema secondary to branch retinal vein occlusion"],"prefix":"10.1007","author":[{"given":"Dong Hyeon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Ha","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Sun","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Il Joong","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoo Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Rock","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Koo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6911-3765","authenticated-orcid":false,"given":"Dong Ho","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"7581_CR1","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","volume":"117","author":"S Rogers","year":"2010","unstructured":"Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, Kowalski JW, Nguyen H, Wong TY, International Eye Disease Consortium (2010) The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117:313\u2013319e1. https:\/\/doi.org\/10.1016\/j.ophtha.2009.07.017","journal-title":"Ophthalmology"},{"key":"7581_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/02713680701851902","volume":"33","author":"J Rehak","year":"2008","unstructured":"Rehak J, Rehak M (2008) Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res 33:111\u2013131. https:\/\/doi.org\/10.1080\/02713680701851902","journal-title":"Curr Eye Res"},{"key":"7581_CR3","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/BF00164677","volume":"233","author":"RM Silva","year":"1995","unstructured":"Silva RM, Faria de Abreu JR, Cunha-Vaz JG (1995) Blood-retina barrier in acute retinal branch vein occlusion. Graefes Arch Clin Exp Ophthalmol 233:721\u2013726. https:\/\/doi.org\/10.1007\/BF00164677","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7581_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00417-004-1087-4","volume":"244","author":"H Noma","year":"2006","unstructured":"Noma H, Minamoto A, Funatsu H, Tsukamoto H, Nakano K, Yamashita H, Mishima HK (2006) Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 244:309\u2013315. https:\/\/doi.org\/10.1007\/s00417-004-1087-4","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7581_CR5","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","volume":"117","author":"PA Campochiaro","year":"2010","unstructured":"Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG, Investigators BRAVO (2010) Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117:1102\u20131112e1. https:\/\/doi.org\/10.1016\/j.ophtha.2010.02.021","journal-title":"Ophthalmology"},{"key":"7581_CR6","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.ophtha.2014.08.031","volume":"122","author":"PA Campochiaro","year":"2015","unstructured":"Campochiaro PA, Clark WL, Boyer DS, Heier JS, Brown DM, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW, Soo Y, Cheng Y, Haller JA (2015) Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology 122:538\u2013544. https:\/\/doi.org\/10.1016\/j.ophtha.2014.08.031","journal-title":"Ophthalmology"},{"key":"7581_CR7","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1136\/bjophthalmol-2014-306543","volume":"99","author":"R Narayanan","year":"2015","unstructured":"Narayanan R, Panchal B, Das T, Chhablani J, Jalali S, Ali MH, MARVEL Study Group (2015) A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report 1. Br J Ophthalmol 99:954\u2013959. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-306543","journal-title":"Br J Ophthalmol"},{"key":"7581_CR8","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.oret.2019.12.019","volume":"4","author":"MJC Vader","year":"2020","unstructured":"Vader MJC, Schauwvlieghe AME, Verbraak FD, Dijkman G, Hooymans JMM, Los LI, Zwinderman AH, Peto T, Hoyng CB, van Leeuwen R, Vingerling JR, de Jong-Hesse Y, van Lith-Verhoeven JJC, Dijkgraaf MGW, Schlingemann RO, Bevacizumab to Ranibizumab in Retinal Vein Occlusions Study Group (2020) Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Retinal Vein Occlusion: The Bevacizumab to Ranibizumab in Retinal Vein Occlusions (BRVO) study, a Randomized Trial. Ophthalmol Retina 4:576\u2013587. https:\/\/doi.org\/10.1016\/j.oret.2019.12.019","journal-title":"Ophthalmol Retina"},{"key":"7581_CR9","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.ajo.2008.05.036","volume":"146","author":"TU Krohne","year":"2008","unstructured":"Krohne TU, Eter N, Holz FG, Meyer CH (2008) Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 146:508\u2013512. https:\/\/doi.org\/10.1016\/j.ajo.2008.05.036","journal-title":"Am J Ophthalmol"},{"key":"7581_CR10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ophtha.2013.08.038","volume":"121","author":"PA Campochiaro","year":"2014","unstructured":"Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, Marcus DM, Feiner L, Patel A, RETAIN Study Group (2014) Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 121:209\u2013219. https:\/\/doi.org\/10.1016\/j.ophtha.2013.08.038","journal-title":"Ophthalmology"},{"key":"7581_CR11","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1097\/ICU.0b013e328338679a","volume":"21","author":"KM Sampat","year":"2010","unstructured":"Sampat KM, Garg SJ (2010) Complications of intravitreal injections. Curr Opin Ophthalmol 21:178\u2013183. https:\/\/doi.org\/10.1097\/ICU.0b013e328338679a","journal-title":"Curr Opin Ophthalmol"},{"key":"7581_CR12","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/j.ophtha.2010.12.034","volume":"118","author":"WE Smiddy","year":"2011","unstructured":"Smiddy WE (2011) Economic considerations of macular edema therapies. Ophthalmology 118:1827\u20131833. https:\/\/doi.org\/10.1016\/j.ophtha.2010.12.034","journal-title":"Ophthalmology"},{"key":"7581_CR13","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1007\/s10792-021-01798-x","volume":"41","author":"Y An","year":"2021","unstructured":"An Y, Park SP, Kim YK (2021) Aqueous humor inflammatory cytokine levels and choroidal thickness in patients with macular edema associated with branch retinal vein occlusion. Int Ophthalmol 41:2433\u20132444. https:\/\/doi.org\/10.1007\/s10792-021-01798-x","journal-title":"Int Ophthalmol"},{"key":"7581_CR14","doi-asserted-by":"publisher","first-page":"5185128","DOI":"10.1155\/2019\/5185128","volume":"2019","author":"H Noma","year":"2019","unstructured":"Noma H, Yasuda K, Shimura M (2019) Cytokines and the Pathogenesis of Macular Edema in Branch Retinal Vein Occlusion. J Ophthalmol 2019:5185128. https:\/\/doi.org\/10.1155\/2019\/5185128","journal-title":"J Ophthalmol"},{"key":"7581_CR15","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.3341\/jkos.2015.56.8.1208","volume":"56","author":"SH Kwon","year":"2015","unstructured":"Kwon SH, Shin JP, Kim IT, Park DH (2015) Efficacy of Intravitreal Dexamethasone Implant for Macular Edema Due to Branch Retinal Vein Occlusion According to Symptom Duration. J Korean Ophthalmol Soc 56:1208\u20131214. https:\/\/doi.org\/10.3341\/jkos.2015.56.8.1208","journal-title":"J Korean Ophthalmol Soc"},{"key":"7581_CR16","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1097\/IAE.0000000000000860","volume":"36","author":"A Russo","year":"2016","unstructured":"Russo A, Morescalchi F, Vezzoli S, Bernini M, Turano R, Costagliola C, De Ferrari F, Semeraro F (2016) Reduction of Vitreous Prostaglandin E2 Levels after Topical Administration of Indomethacin 0.5%, Bromfenac 0.09%, and Nepafenac 0.1%. Retina 36:1227\u20131231. https:\/\/doi.org\/10.1097\/IAE.0000000000000860","journal-title":"Retina"},{"key":"7581_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3341\/jkos.2024.65.1.27","volume":"65","author":"MS Kwon","year":"2024","unstructured":"Kwon MS, Kim JY, Kim YM, Do JR, Kang YK, Shin JP, Park DH (2024) Clinical Outcomes of Topical Bromfenac Combined with Intravitreal Aflibercept Injection for Exudative Age-related Macular Degeneration. J Korean Ophthalmol Soc 65:27\u201334. https:\/\/doi.org\/10.3341\/jkos.2024.65.1.27","journal-title":"J Korean Ophthalmol Soc"},{"key":"7581_CR18","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1136\/bjophthalmol-2013-304720","volume":"99","author":"M Shimura","year":"2015","unstructured":"Shimura M, Yasuda K (2015) Topical bromfenac reduces the frequency of intravitreal bevacizumab in patients with branch retinal vein occlusion. Br J Ophthalmol 99:215\u2013219. https:\/\/doi.org\/10.1136\/bjophthalmol-2013-304720","journal-title":"Br J Ophthalmol"},{"key":"7581_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3341\/jkos.2020.61.2.183","volume":"61","author":"JM Yun","year":"2020","unstructured":"Yun JM, Cho YW, Moon JW (2020) Bromfenac as Adjunctive Treatment with Intravitreal Bevacizumab in Branch Retinal Vein Occlusion of Macular Edema. J Korean Ophthalmol Soc 61:183\u2013189. https:\/\/doi.org\/10.3341\/jkos.2020.61.2.183","journal-title":"J Korean Ophthalmol Soc"},{"key":"7581_CR20","doi-asserted-by":"publisher","first-page":"10162","DOI":"10.1038\/s41598-022-14386-5","volume":"12","author":"Y Mun","year":"2022","unstructured":"Mun Y, Park C, Lee DY, Kim TM, Jin KW, Kim S, Chung YR, Lee K, Song JH, Roh YJ, Jee D, Kwon JW, Woo SJ, Park KH, Park RW, Yoo S, Chang DJ, Park SJ (2022) Real-world treatment intensities and pathways of macular edema following retinal vein occlusion in Korea from Common Data Model in ophthalmology. Sci Rep 12:10162. https:\/\/doi.org\/10.1038\/s41598-022-14386-5","journal-title":"Sci Rep"},{"key":"7581_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00417-022-05755-x","volume":"261","author":"R Cohen","year":"2023","unstructured":"Cohen R, Shor R, Segal O, Greenbaum E, Ayalon A, Trivizki O, Schwartz S, Loewenstein A, Rabina G (2023) Postponed care due to COVID-19 lockdown impact on visual acuity of retinal vein occlusion patients: a large cohort. Graefes Arch Clin Exp Ophthalmol 261:43\u201348. https:\/\/doi.org\/10.1007\/s00417-022-05755-x","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7581_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/BF00156415","volume":"19","author":"MB Parodi","year":"1995","unstructured":"Parodi MB, Visintin F, Della Rupe P, Ravalico G (1995) Foveal avascular zone in macular branch retinal vein occlusion. Int Ophthalmol 19:25\u201328. https:\/\/doi.org\/10.1007\/BF00156415","journal-title":"Int Ophthalmol"},{"key":"7581_CR23","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1001\/archopht.1992.01080220089028","volume":"110","author":"D Finkelstein","year":"1992","unstructured":"Finkelstein D (1992) Ischemic macular edema. Recognition and favorable natural history in branch vein occlusion. Arch Ophthalmol 110:1427\u20131434. https:\/\/doi.org\/10.1001\/archopht.1992.01080220089028","journal-title":"Arch Ophthalmol"},{"key":"7581_CR24","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1177\/1120672117750058","volume":"28","author":"F Bandello","year":"2018","unstructured":"Bandello F, Augustin A, Tufail A, Leaback R (2018) A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion. Eur J Ophthalmol 28:697\u2013705. https:\/\/doi.org\/10.1177\/1120672117750058","journal-title":"Eur J Ophthalmol"},{"key":"7581_CR25","doi-asserted-by":"publisher","first-page":"209735","DOI":"10.1155\/2013\/209735","volume":"2013","author":"SJ Ahn","year":"2013","unstructured":"Ahn SJ, Ahn J, Woo SJ, Park KH (2013) Initial dose of three monthly intravitreal injections versus PRN intravitreal injections of bevacizumab for macular edema secondary to branch retinal vein occlusion. Biomed Res Int 2013:209735. https:\/\/doi.org\/10.1155\/2013\/209735","journal-title":"Biomed Res Int"},{"key":"7581_CR26","doi-asserted-by":"publisher","first-page":"8421940","DOI":"10.1155\/2016\/8421940","volume":"2016","author":"JK Wang","year":"2016","unstructured":"Wang JK, Su PY, Hsu YR, Chen YJ, Chen FT, Tseng YY (2016) Comparison of the Efficacy of Intravitreal Aflibercept and Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion. J Ophthalmol 2016:8421940. https:\/\/doi.org\/10.1155\/2016\/8421940","journal-title":"J Ophthalmol"},{"key":"7581_CR27","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s00417-008-0898-0","volume":"246","author":"J Riese","year":"2008","unstructured":"Riese J, Loukopoulos V, Meier C, Timmermann M, Gerding H (2008) Combined intravitreal triamcinolone injection and laser photocoagulation in eyes with persistent macular edema after branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 246:1671\u20131676. https:\/\/doi.org\/10.1007\/s00417-008-0898-0","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7581_CR28","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3928\/23258160-20190605-03","volume":"50","author":"JJ Yu","year":"2019","unstructured":"Yu JJ, Thomas AS, Berry D, Yoon S, Fekrat S, Grewal DS (2019) Association of Retinal Inner Layer Disorganization With Ultra-Widefield Fluorescein Angiographic Features and Visual Acuity in Branch Retinal Vein Occlusion. Ophthalmic Surg Lasers Imaging Retina 50:354\u2013364. https:\/\/doi.org\/10.3928\/23258160-20190605-03","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"7581_CR29","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ajo.2017.08.005","volume":"182","author":"M Mimouni","year":"2017","unstructured":"Mimouni M, Segev O, Dori D, Geffen N, Flores V, Segal O (2017) Disorganization of the Retinal Inner Layers as a Predictor of Visual Acuity in Eyes With Macular Edema Secondary to Vein Occlusion. Am J Ophthalmol 182:160\u2013167. https:\/\/doi.org\/10.1016\/j.ajo.2017.08.005","journal-title":"Am J Ophthalmol"},{"key":"7581_CR30","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1001\/jamaophthalmol.2014.2350","volume":"132","author":"JK Sun","year":"2014","unstructured":"Sun JK, Lin MM, Lammer J, Prager S, Sarangi R, Silva PS, Aiello LP (2014) Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema. JAMA Ophthalmol 132:1309\u20131316. https:\/\/doi.org\/10.1001\/jamaophthalmol.2014.2350","journal-title":"JAMA Ophthalmol"},{"key":"7581_CR31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1167\/iovs.15-18304","volume":"57","author":"JH Kim","year":"2016","unstructured":"Kim JH, Shin JP, Kim IT, Park DH (2016) Aqueous angiopoietin-like 4 levels correlate with nonperfusion area and macular edema in branch retinal vein occlusion. Invest Ophthalmol Vis Sci 57:6\u201311. https:\/\/doi.org\/10.1167\/iovs.15-18304","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"7581_CR32","doi-asserted-by":"publisher","first-page":"1856268","DOI":"10.3389\/fmed.2026.1856268","volume":"13","author":"X Li","year":"2026","unstructured":"Li X, Yang L, Long H, Li X (2026) Baseline predictors of visual response and treatment burden after ranibizumab therapy in macular edema secondary to retinal vein occlusion. Front Med (Lausanne) 13:1856268. https:\/\/doi.org\/10.3389\/fmed.2026.1856268","journal-title":"Front Med (Lausanne)"},{"key":"7581_CR33","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.oret.2022.02.008","volume":"6","author":"D Nagasato","year":"2022","unstructured":"Nagasato D, Muraoka Y, Tanabe M, Nishigori N, Osaka R, Mitamura Y, Tabuchi H, Kadomoto S, Murakami T, Ooto S, Suzuma K, Tsujikawa A (2022) Foveal Thickness Fluctuation in Anti-VEGF Treatment for Branch Retinal Vein Occlusion: A Long-term Study. Ophthalmol Retina 6:567\u2013574. https:\/\/doi.org\/10.1016\/j.oret.2022.02.008","journal-title":"Ophthalmol Retina"},{"key":"7581_CR34","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1038\/s41433-021-01620-z","volume":"36","author":"KL Spooner","year":"2022","unstructured":"Spooner KL, Fraser-Bell S, Hong T, Wong JG, Chang AA (2022) Long-term outcomes of anti-VEGF treatment of retinal vein occlusion. Eye 36:1194\u20131201. https:\/\/doi.org\/10.1038\/s41433-021-01620-z","journal-title":"Eye"},{"key":"7581_CR35","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.oret.2024.04.014","volume":"8","author":"S Alforja","year":"2024","unstructured":"Alforja S, Hunt A, Nguyen V, O\u2019Toole L, Gabrielle PH, Invernizzi A, Mehta H, Ponsioen TL, Squirrell D, Casaroli-Marano RP, Barthelmes D, Gillies MC, Zarranz-Ventura J, Fight Retinal Blindness Study Group (2024) Three-Year Outcomes of VEGF Inhibitors in Naive Branch Retinal Vein Occlusion: Fight Retinal Blindness! Ophthalmol Retina 8:962\u2013970. https:\/\/doi.org\/10.1016\/j.oret.2024.04.014","journal-title":"Ophthalmol Retina"},{"key":"7581_CR36","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s00417-020-04932-0","volume":"259","author":"JV Costa","year":"2021","unstructured":"Costa JV, Moura-Coelho N, Abreu AC, Neves P, Ornelas M, Furtado MJ (2021) Macular edema secondary to retinal vein occlusion in a real-life setting: a multicenter, nationwide, 3-year follow-up study. Graefes Arch Clin Exp Ophthalmol 259:343\u2013350. https:\/\/doi.org\/10.1007\/s00417-020-04932-0","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7581_CR37","doi-asserted-by":"publisher","first-page":"7661","DOI":"10.1038\/s41598-022-11113-y","volume":"12","author":"T Murata","year":"2022","unstructured":"Murata T, Kondo M, Inoue M, Nakao S, Osaka R, Shiragami C, Sogawa K, Mochizuki A, Shiraga R, Kaneko T, Chandrasekhar C, Tsujikawa A, Kamei M (2022) Estimating ranibizumab injection numbers and visual acuity at 12 months based on 2-month data on branch retinal vein occlusion treatment. Sci Rep 12:7661. https:\/\/doi.org\/10.1038\/s41598-022-11113-y","journal-title":"Sci Rep"},{"key":"7581_CR38","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41433-025-04089-2","volume":"40","author":"C Dinah","year":"2026","unstructured":"Dinah C, Dodds M, Lotery A, Salvatore S, Fletcher E, Lake AVR, Parker A, Paris Pereira L, Retiere AC, Saffar I, Arrisi P, United Kingdom Retinal Vein Occlusion Electronic Medical Records Users Group, Chi GC (2026) Treatment patterns and long-term outcomes in anti-VEGF-treated macular oedema secondary to retinal vein occlusion: a retrospective observational study. Eye 40:107\u2013116. https:\/\/doi.org\/10.1038\/s41433-025-04089-2","journal-title":"Eye"},{"key":"7581_CR39","doi-asserted-by":"publisher","first-page":"12068","DOI":"10.1038\/s41598-023-39303-2","volume":"13","author":"YR Chung","year":"2023","unstructured":"Chung YR, Woo TK, Park HR, Lee K (2023) Efficacy of as-needed intravitreal injection compared to 3-monthly loading of anti-vascular endothelial growth factor agents for branch retinal vein occlusion. Sci Rep 13:12068. https:\/\/doi.org\/10.1038\/s41598-023-39303-2","journal-title":"Sci Rep"},{"key":"7581_CR40","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00417-019-04495-9","volume":"258","author":"M Suzuki","year":"2020","unstructured":"Suzuki M, Nagai N, Minami S, Kurihara T, Kamoshita M, Sonobe H, Watanabe K, Shinoda H, Tsubota K, Ozawa Y (2020) Predicting recurrences of macular edema due to branch retinal vein occlusion during anti-vascular endothelial growth factor therapy. Graefes Arch Clin Exp Ophthalmol 258:49\u201356. https:\/\/doi.org\/10.1007\/s00417-019-04495-9","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7581_CR41","doi-asserted-by":"publisher","first-page":"16200","DOI":"10.1038\/s41598-019-52732-2","volume":"9","author":"R Tomita","year":"2019","unstructured":"Tomita R, Iwase T, Goto K, Yamamoto K, Ra E, Terasaki H (2019) Correlation between macular vessel density and number of intravitreal anti-VEGF agents for macular edema associated with branch retinal vein occlusion. Sci Rep 9:16200. https:\/\/doi.org\/10.1038\/s41598-019-52732-2","journal-title":"Sci Rep"},{"key":"7581_CR42","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1167\/iovs.08-2510","volume":"50","author":"M Funk","year":"2009","unstructured":"Funk M, Kriechbaum K, Prager F, Benesch T, Georgopoulos M, Zlabinger GJ, Schmidt-Erfurth U (2009) Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci 50:1025\u20131032. https:\/\/doi.org\/10.1167\/iovs.08-2510","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"7581_CR43","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1471-2415-14-67","volume":"14","author":"H Noma","year":"2014","unstructured":"Noma H, Mimura T, Shimada K (2014) Role of inflammation in previously untreated macular edema with branch retinal vein occlusion. BMC Ophthalmol 14:67. https:\/\/doi.org\/10.1186\/1471-2415-14-67","journal-title":"BMC Ophthalmol"},{"key":"7581_CR44","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ajo.2012.03.047","volume":"154","author":"TU Krohne","year":"2012","unstructured":"Krohne TU, Liu Z, Holz FG, Meyer CH (2012) Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol 154:682\u2013686e2. https:\/\/doi.org\/10.1016\/j.ajo.2012.03.047","journal-title":"Am J Ophthalmol"},{"key":"7581_CR45","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/j.ophtha.2008.04.023","volume":"115","author":"Q Zhu","year":"2008","unstructured":"Zhu Q, Ziemssen F, Henke-Fahle S, Tatar O, Szurman P, Aisenbrey S, Schneiderhan-Marra N, Xu X, Tubingen Bevacizumab Study Group, Grisanti S (2008) Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology 115:1750\u20131755e1. https:\/\/doi.org\/10.1016\/j.ophtha.2008.04.023","journal-title":"Ophthalmology"},{"key":"7581_CR46","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.survophthal.2009.07.005","volume":"55","author":"SJ Kim","year":"2010","unstructured":"Kim SJ, Flach AJ, Jampol LM (2010) Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol 55:108\u2013133. https:\/\/doi.org\/10.1016\/j.survophthal.2009.07.005","journal-title":"Surv Ophthalmol"},{"key":"7581_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.survophthal.2019.07.001","volume":"65","author":"B Rigas","year":"2020","unstructured":"Rigas B, Huang W, Honkanen R (2020) NSAID-induced corneal melt: Clinical importance, pathogenesis, and risk mitigation. Surv Ophthalmol 65:1\u201311. https:\/\/doi.org\/10.1016\/j.survophthal.2019.07.001","journal-title":"Surv Ophthalmol"},{"key":"7581_CR48","doi-asserted-by":"publisher","first-page":"741","DOI":"10.2147\/OPTH.S41801","volume":"7","author":"K Yanai","year":"2013","unstructured":"Yanai K, Huang J, Kadonosono K, Uchio E (2013) Corneal sensitivity after topical bromfenac sodium eye-drop instillation. Clin Ophthalmol 7:741\u2013744. https:\/\/doi.org\/10.2147\/OPTH.S41801","journal-title":"Clin Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07581-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-026-07581-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07581-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:01:51Z","timestamp":1792785711000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-026-07581-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":48,"alternative-id":["7581"],"URL":"https:\/\/doi.org\/10.1007\/s00417-026-07581-x","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"18 September 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was approved by the Institutional Review Board of Kyungpook National University Hospital (IRB No. 2026-07-007) and was conducted in accordance with the tenets of the Declaration of Helsinki. The requirement for informed consent was waived by the Institutional Review Board owing to the retrospective design and the use of de-identified data.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}